H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Nurix Therapeutics to $33 from $53 and keeps a Buy rating on the shares after the company presented three series of results – clinical datasets for NX-2127 and NX-5948 and a preclinical dataset for NX-594.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NRIX:
- Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
- Is NRIX a Buy, Before Earnings?
- Nurix Therapeutics assumed with an Outperform at Oppenheimer
- Nurix Therapeutics presents data on NX-5948, NX-2127
- Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications